Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Clinical trial NCT07745257 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07745257
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-28
- Primary completion
- 2027-12-28
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.